Share Prices & Company Research

Market News

20 Nov 2020 | 08:53

Citi ups rating on Croda following Iberchem deal

(Sharecast News) - Citi has upgraded Croda International to a 'buy' following the chemicals group's €820m acquisition of Spain's Iberchem. The UK firm, which has secured a contract to supply ingredients for Pfizer's Covid-19 vaccine, announced on Wednesday that it had agreed to buy the fragrances firm, a specialist in emerging markets, from its private equity owners.

Citi said the deal was a "step change".

Analyst Mubasher Chaudhry said: "The deal, we think, provides Croda with access to the fastest-growing regions within the fragrance space, the ability to realise significant revenue synergies through cross-selling, and an opportunity to partake in what is a rapidly consolidating industry.

"Double digit growth in life sciences, increased markets to growing in personal care, and a strong balance sheet to support inorganic growth presents a compelling investment case."

Around 83% of Iberchem sales are in emerging markets.

As at 0935 GMT, shares in Croda were ahead nearly 2% at 6,358.0p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 15th January 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.